Compass Pathways reports positive one-year data for its psilocybin therapy COMP360

Compass Pathways released results from a one-year study of its psilocybin‑based therapy COMP360. The company described the data as positive, indicating continued promise for the investigational treatment.

The findings were presented without detailed efficacy numbers, but the tone suggested the trial met key endpoints and supported further development.

In a separate market update, Solstice announced a debut that raised $225 million, highlighting strong investor interest in its platform.

These developments were part of a broader industry briefing that also mentioned activities at Luma, Inno Medicine, Schrödinger, Assembly Biosciences, Gilead, Leyden Labs, Navion, Ridge Bio, and Opus Genetics.